Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
By M. Atkins, M. Hidalgo, W. Stadler, T. Logan, J. Dutcher, G. Hudes, Young Park, S. Liou, Bonnie Marshall, J. Boni and 2 more. Journal of Clinical Oncology, 2004
943 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/c57a728ad314f455eb6bfe4743442b0f8b46049c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
- Guido Kroemer
- T. Mak
- Yiling Lu
- Arnold J. Levine
- Bryan T. J. Hennessy
- Gordon B. Mills
- C. Sawyers
- Jean J. Zhao
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis (2006, background): “In particular, CCI-779 has proven to be of clinical benefit to patients with breast or renal carcinoma”
- Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer (2009, result): “Results from recent clinical studies with temsirolimus and everolimus used as single agents showed that these drugs improved survival in patients with advanced renal cell carcinoma, leading to approval of these compounds for this indicatio”
- Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery (2005, methodology): “CCI-779 showed activity in Phase II clinical studies in patients with renal cell carcinoma and glioblastoma who have previously been treated with current standard therapies, and is being evaluated in combination with the aromatase inhibitor letrozole in metastatic breast cancer in a Phase III stud”
- Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010, background): “Noninfectious pneumonitis is an adverse reaction associated with rapamycin and rapamycin analogues.(11) Awareness of this toxicity and appropriate diagnostic and medical management is important to optimize patient safety.”
- Targeting Apoptosis Pathways in Cancer Therapy (2005, background): “cell carcinoma had a complete or partial response, and 26% had minor responses.(110) Phase III trials for renal cell carcinoma are ongoing.”
- Current development of mTOR inhibitors as anticancer agents (2006, methodology): “CCI-779 was also investigated in a large dose-randomized Phase II study of patients with advanced renal cell carcinomas that were classified in three groups according to Motzer's criteria (good, intermediate and poor prognosis”